JP Morgan Chase’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-159,857
| Closed | -$3.78M | – | 8029 |
|
|
2023
Q4 | $3.78M | Sell |
159,857
-202,830
| -56% | -$3.61M | ﹤0.01% | 3327 |
|
|
2023
Q3 | $5.41M | Sell |
362,687
-60,774
| -14% | -$806K | ﹤0.01% | 2776 |
|
|
2023
Q2 | $4.64M | Sell |
423,461
-118,946
| -22% | -$1.11M | ﹤0.01% | 2926 |
|
|
2023
Q1 | $4.73M | Buy |
542,407
+539,415
| +18,029% | +$4.32M | ﹤0.01% | 2862 |
|
|
2022
Q4 | $19K | Sell |
2,992
-3,331
| -53% | -$12.7K | ﹤0.01% | 5911 |
|
|
2022
Q3 | $22K | Buy |
6,323
+2,980
| +89% | +$10.7K | ﹤0.01% | 5782 |
|
|
2022
Q2 | $10K | Sell |
3,343
-1,300,368
| -100% | -$3.11M | ﹤0.01% | 6041 |
|
|
2022
Q1 | $4.05M | Sell |
1,303,711
-78,835
| -6% | -$248K | ﹤0.01% | 3182 |
|
|
2021
Q4 | $4.67M | Buy |
1,382,546
+51,271
| +4% | +$195K | ﹤0.01% | 3114 |
|
|
2021
Q3 | $4.86M | Buy |
1,331,275
+1,301,429
| +4,360% | +$5.13M | ﹤0.01% | 3049 |
|
|
2021
Q2 | $130K | Sell |
29,846
-60,621
| -67% | -$269K | ﹤0.01% | 5447 |
|
|
2021
Q1 | $410K | Buy |
90,467
+7,903
| +10% | +$42.5K | ﹤0.01% | 4805 |
|
|
2020
Q4 | $474K | Buy |
82,564
+56,742
| +220% | +$430K | ﹤0.01% | 4398 |
|
|
2020
Q3 | $183K | Buy |
25,822
+2,515
| +11% | +$13.4K | ﹤0.01% | 4404 |
|
|
2020
Q2 | $81K | Sell |
23,307
-763,101
| -97% | -$2.2M | ﹤0.01% | 4657 |
|
|
2020
Q1 | $1.16M | Buy |
786,408
+763,825
| +3,382% | +$1.28M | ﹤0.01% | 3312 |
|
|
2019
Q4 | $44K | Sell |
22,583
-460,816
| -95% | -$1.73M | ﹤0.01% | 5169 |
|
|
2019
Q3 | $2.48M | Buy |
483,399
+464,479
| +2,455% | +$2.81M | ﹤0.01% | 3266 |
|
|
2019
Q2 | $132K | Sell |
18,920
-277,583
| -94% | -$3.14M | ﹤0.01% | 4826 |
|
|
2019
Q1 | $3.94M | Sell |
296,503
-19,223
| -6% | -$204K | ﹤0.01% | 2788 |
|
|
2018
Q4 | $2.48M | Buy |
315,726
+302,078
| +2,213% | +$2.88M | ﹤0.01% | 3126 |
|
|
2018
Q3 | $151K | Sell |
13,648
-34,453
| -72% | -$428K | ﹤0.01% | 4794 |
|
|
2018
Q2 | $646K | Buy |
48,101
+10,316
| +27% | +$129K | ﹤0.01% | 4056 |
|
|
2018
Q1 | $491K | Buy |
+37,785
| New | +$469K | ﹤0.01% | 4021 |
|
|
2016
Q3 | – | Sell |
-100
| Closed | – | – | 4876 |
|
|
2016
Q2 | $0 | Buy |
+100
| New | +$207 | ﹤0.01% | 5011 |
|
|
2015
Q3 | – | Sell |
-25,000
| Closed | -$67K | – | 4123 |
|
|
2015
Q2 | $67K | Buy |
+25,000
| New | +$103K | ﹤0.01% | 3903 |
|
Other funds holding CBAY
JP Morgan Chase's CBAY Position: Q1 2024 in Review
JP Morgan Chase sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 159,857 shares — an estimated $3.78M sold.
JP Morgan Chase first reported a position in CBAY in Q2 2015 and held it in 26 quarters. The position peaked at $5.41M in Q3 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- JP Morgan Chase reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- JP Morgan Chase sold 159,857 Cymabay Therapeutics shares in Q1 2024, an estimated $3.78M.
- JP Morgan Chase first reported a position in Cymabay Therapeutics in Q2 2015 and held it in 26 quarters.
- JP Morgan Chase's Cymabay Therapeutics position peaked at $5.41M in Q3 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.